Clin Psychopharmacol Neurosci.
2024 May;22(2):370-375. 10.9758/cpn.23.1106.
The Potential Role of Aripiprazole Augmentation for Major Depressive Disorder with Anxious Distress in Naturalistic Treatment Setting
- Affiliations
-
- 1Department of Psychiatry, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea
- 2Department of Dermatology, Bucheon St. Mary’s Hospital, The Catholic University of Korea College of Medicine, Bucheon, Korea
- 3Cell Death Disease Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea
- 4Yonsei St. Mary’s Mental Clinic, Bucheon, Korea
- 5Department of Psychiatry, The Catholic University of Korea College of Medicine, Seoul, Korea
- 6Avance Psychiatry at Centers of Excellence, Raleigh, NC, USA
- 7Duke-NUS Medical School, Singapore
- KMID: 2556430
- DOI: http://doi.org/10.9758/cpn.23.1106
Abstract
Objective
This study tried to observe clinical benefit of aripiprazole augmentation (ARPA) treatment for major depressive disorder with anxious distress (MDDA) in routine practice.
Methods
Retrospective chart review (n = 41) was conducted for clinical benefit of ARPA in patients with MDDA in routine practice. The primary endpoint was the mean change of Hamilton Anxiety Rating scale (HAMA) total scores from baseline to the endpoint. Additional secondary endpoints were also retrieved.
Results
The changes of primary endpoint HAMA (t = 5.731, −4.6, p = 0.001), and secondary endpoints including Hamilton Depression Rating scale (HAMD, t = 4.284, −3.4, p ＜ 0.001), Clinical Global Impression-Clinical Benefit (CGI-CB, −0.9, t = 1.821, p = 0.026), and Clinical Global Impression Score-Severity (CGI-S, t = 3.556, −0.4, p ＜ 0.001) scores were also significantly improved during the study. No significant adverse events were observed.
Conclusion
This study has shown additional benefit of ARPA treatment for MDDA patients in routine practice. However, adequately-powered and well-controlled studies are necessary for generalization of the present findings.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Difference in Treatment Outcome in Hospitalized Major Depression Patients with versus without Anxious Distress Specifier in DSM-5
- The Potential Utility of Aripiprazole Augmentation for Major Depressive Disorder with Mixed Features Specifier: A Retrospective Study
- Optimizing the Use of Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: From Clinical Trials to Clinical Practice
- Factor Structure of the Hamilton Depression Rating Scale for Patients with Major Depression with the Anxious Distress Specifier in DSM-5
- Successful Early Lamotrigine and Aripiprazole Augmentation of Clomipramine in Severe Obsessive-compulsive Disorder
